Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

P-glycoprotein: a clue to vitamin K antagonist stabilization.

Pharmacogenomics - 1 Jan 2015

Gschwind Liliane, Rollason Victoria, Boehlen Françoise, Rebsamen Michela, Combescure Christophe, Matthey Alain, Bonnabry Pascal, Dayer Pierre, Desmeules Jules Alexandre

Abstract excerpt

BACKGROUND: Acenocoumarol is a vitamin K antagonist used in some European countries. As warfarin, this drug is characterized by a narrow therapeutic index and a large interindividual variability. AIM: The objective of this study was to assess the involvement of ABCB1 polymorphisms on acenocoumaro...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acenocoumarol
Share to Anticoagulants
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to International Normalized Ratio

Share to Polymorphism, Genetic

Share to Thromboembolism

Share to Treatment Outcome

Share to Vitamin K

Source

Identifiers

PMID: 25616099
DOI: 10.2217/pgs.14.164

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25616099-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

P-glycoprotein: a clue to vitamin K antagonist stabilization.PMID 25616099Read ↗

[Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].Semantic proximity Read ↗

Pharmacogenetics role in the safety of acenocoumarol therapy.Semantic proximity Read ↗

Clinical and genetic factors influencing acenocoumarol dosing: a cross-sectional study.Semantic proximity Read ↗

The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy.Semantic proximity Read ↗

The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation.Semantic proximity Read ↗

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.Semantic proximity Read ↗

Acenocoumarol stabilization is delayed in CYP2C93 carriers.Semantic proximity Read ↗

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.Semantic proximity Read ↗

Creating a genotype-based dosing algorithm for acenocoumarol steady dose.Semantic proximity Read ↗

Influence of two variants of CYP450 oxidoreductase on the stable dose of acenocoumarol in a Spanish population.Semantic proximity Read ↗

Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients.Semantic proximity Read ↗

Risk Factors for Rivaroxaban-Related Bleeding Events—Possible Role of Pharmacogenetics: Case SeriesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.